12:00 AM
 | 
Jun 05, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AP1903: Phase I data; Phase II

In a Phase I trial in 20 healthy volunteers, AP1903 was well tolerated with no side effects or toxicity over a range of doses, and showed predictable dose-responsive...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >